<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33080984</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Identification and Tracking of Antiviral Drug Combinations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1178</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v12101178</ELocationID><Abstract><AbstractText>Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ianevski</LastName><ForeName>Aleksandr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Rouan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biza</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zusinaite</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Technology, University of Tartu, 50090 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mannik</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Icosagen Cell Factory O&#xdc;, 61713 Kambja vald Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivi</LastName><ForeName>Gaily</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Icosagen Cell Factory O&#xdc;, 61713 Kambja vald Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Planken</LastName><ForeName>Anu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Icosagen Cell Factory O&#xdc;, 61713 Kambja vald Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurg</LastName><ForeName>Kristiina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Icosagen Cell Factory O&#xdc;, 61713 Kambja vald Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tombak</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Icosagen Cell Factory O&#xdc;, 61713 Kambja vald Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ustav</LastName><ForeName>Mart</ForeName><Initials>M</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Icosagen Cell Factory O&#xdc;, 61713 Kambja vald Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shtaida</LastName><ForeName>Nastassia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Technology, University of Tartu, 50090 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulesskiy</LastName><ForeName>Evgeny</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Eunji</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Applied Molecular Virology Laboratory, Institut Pasteur Korea, Sampyeong-dong 696, Bundang-gu, Seongnam-si 463-400, Gyeonggi-do, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jaewon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Applied Molecular Virology Laboratory, Institut Pasteur Korea, Sampyeong-dong 696, Bundang-gu, Seongnam-si 463-400, Gyeonggi-do, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lysvand</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf8;seth</LastName><ForeName>Kirsti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oksenych</LastName><ForeName>Valentyn</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5088-3791</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aas</LastName><ForeName>Per Arne</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenson</LastName><ForeName>Tanel</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0260-3601</Identifier><AffiliationInfo><Affiliation>Institute of Technology, University of Tartu, 50090 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitkauskien&#x117;</LastName><ForeName>Astra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Lithuanian University of Health Science, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windisch</LastName><ForeName>Marc P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Applied Molecular Virology Laboratory, Institut Pasteur Korea, Sampyeong-dong 696, Bundang-gu, Seongnam-si 463-400, Gyeonggi-do, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenstad</LastName><ForeName>Mona H&#xf8;ys&#xe6;ter</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-9102-8409</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordb&#xf8;</LastName><ForeName>Svein Arne</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Transfusion Medicine, St. Olavs Hospital, 7006 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ustav</LastName><ForeName>Mart</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Icosagen Cell Factory O&#xdc;, 61713 Kambja vald Tartumaa, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bj&#xf8;r&#xe5;s</LastName><ForeName>Magnar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kainov</LastName><ForeName>Denis E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Technology, University of Tartu, 50090 Tartu, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014 Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOBTT39</GrantID><Agency>Estonian Research Competency Council</Agency><Country>International</Country></Grant><Grant><GrantID>NRF-2017M3A9G6068246</GrantID><Agency>National Research Foundation of Korea</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062313" MajorTopicYN="N">Databases, Pharmaceutical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral drug combinations</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">broad-spectrum antivirals</Keyword><Keyword MajorTopicYN="N">virus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33080984</ArticleId><ArticleId IdType="pmc">PMC7589631</ArticleId><ArticleId IdType="doi">10.3390/v12101178</ArticleId><ArticleId IdType="pii">v12101178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DALYs G.B.D., Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1260&#x2013;1344. doi: 10.1016/S0140-6736(17)32130-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32130-X</ArticleId><ArticleId IdType="pmc">PMC5605707</ArticleId><ArticleId IdType="pubmed">28919118</ArticleId></ArticleIdList></Reference><Reference><Citation>Disease G.B.D., Injury I., Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211&#x2013;1259. doi: 10.1016/S0140-6736(17)32154-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32154-2</ArticleId><ArticleId IdType="pmc">PMC5605509</ArticleId><ArticleId IdType="pubmed">28919117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri S., Symons J.A., Deval J. Innovation and trends in the development and approval of antiviral medicines: 1987&#x2013;2017 and beyond. Antivir. Res. 2018;155:76&#x2013;88. doi: 10.1016/j.antiviral.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.05.005</ArticleId><ArticleId IdType="pmc">PMC7126013</ArticleId><ArticleId IdType="pubmed">29758235</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.I., Ianevski A., Lysvand H., Vitkauskiene A., Oksenych V., Bjoras M., Telling K., Lutsar I., Dumpis U., Irie Y., et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. Infect. Dis. 2020;93:268&#x2013;276. doi: 10.1016/j.ijid.2020.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.02.018</ArticleId><ArticleId IdType="pmc">PMC7128205</ArticleId><ArticleId IdType="pubmed">32081774</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., Gaelings L., Soderholm S., Belanov S., Nandania J., Nyman T.A., Matikainen S., Anders S., Velagapudi V., Kainov D.E. JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. Antivir. Res. 2016;133:23&#x2013;31. doi: 10.1016/j.antiviral.2016.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.07.008</ArticleId><ArticleId IdType="pubmed">27451344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuivanen S., Bespalov M.M., Nandania J., Ianevski A., Velagapudi V., De Brabander J.K., Kainov D.E., Vapalahti O. Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism. Antivir. Res. 2017;139:117&#x2013;128. doi: 10.1016/j.antiviral.2016.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.12.022</ArticleId><ArticleId IdType="pubmed">28049006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Yao R., Fenstad M.H., Biza S., Zusinaite E., Reisberg T., Lysvand H., Loseth K., Landsem V.M., Malmring J.F., et al. Potential Antiviral Options against SARS-CoV-2 Infection. Viruses. 2020;12:642. doi: 10.3390/v12060642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12060642</ArticleId><ArticleId IdType="pmc">PMC7354438</ArticleId><ArticleId IdType="pubmed">32545799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M., Yang J., Park S., Jo E., Kim H.Y., Bae Y.S., Windisch M.P. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. Antivir. Res. 2016;132:287&#x2013;295. doi: 10.1016/j.antiviral.2016.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.07.002</ArticleId><ArticleId IdType="pubmed">27387825</ArticleId></ArticleIdList></Reference><Reference><Citation>Smura T., Kakkola L., Blomqvist S., Klemola P., Parsons A., Kallio-Kokko H., Savolainen-Kopra C., Kainov D.E., Roivainen M. Molecular evolution and epidemiology of echovirus 6 in Finland. Infect. Genet. Evol. 2013;16:234&#x2013;247. doi: 10.1016/j.meegid.2013.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2013.02.011</ArticleId><ArticleId IdType="pubmed">23462388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M., Yang J., Jo E., Lee J.Y., Kim H.Y., Bartenschlager R., Shin E.C., Bae Y.S., Windisch M.P. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner. Sci. Rep. 2017;7:44676. doi: 10.1038/srep44676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44676</ArticleId><ArticleId IdType="pmc">PMC5363083</ArticleId><ArticleId IdType="pubmed">28333153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosl K., Ianevski A., Than T.T., Andersen P.I., Kuivanen S., Teppor M., Zusinaite E., Dumpis U., Vitkauskiene A., Cox R.J., et al. Common Nodes of Virus&#x2013;Host Interaction Revealed Through an Integrated Network Analysis. Front. Immunol. 2019 doi: 10.3389/fimmu.2019.02186. accepted.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02186</ArticleId><ArticleId IdType="pmc">PMC6787150</ArticleId><ArticleId IdType="pubmed">31636628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Zusinaite E., Kuivanen S., Strand M., Lysvand H., Teppor M., Kakkola L., Paavilainen H., Laajala M., Kallio-Kokko H., et al. Novel activities of safe-in-human broad-spectrum antiviral agents. Antivir. Res. 2018;154:174&#x2013;182. doi: 10.1016/j.antiviral.2018.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.04.016</ArticleId><ArticleId IdType="pmc">PMC7113852</ArticleId><ArticleId IdType="pubmed">29698664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulanova D., Ianevski A., Bugai A., Akimov Y., Kuivanen S., Paavilainen H., Kakkola L., Nandania J., Turunen L., Ohman T., et al. Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses. 2017;9:271. doi: 10.3390/v9100271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v9100271</ArticleId><ArticleId IdType="pmc">PMC5691623</ArticleId><ArticleId IdType="pubmed">28946654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., He L., Aittokallio T., Tang J. SynergyFinder: A web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413&#x2013;2415. doi: 10.1093/bioinformatics/btx162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx162</ArticleId><ArticleId IdType="pmc">PMC5554616</ArticleId><ArticleId IdType="pubmed">28379339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Giri A.K., Aittokallio T. SynergyFinder 2.0: Visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020 doi: 10.1093/nar/gkaa216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa216</ArticleId><ArticleId IdType="pmc">PMC7319457</ArticleId><ArticleId IdType="pubmed">32246720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Potdar S., Ianevski A., Mpindi J.P., Bychkov D., Fiere C., Ianevski P., Yadav B., Wennerberg K., Aittokallio T., Kallioniemi O., et al. Breeze: An integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics. 2020;36:3602&#x2013;3604. doi: 10.1093/bioinformatics/btaa138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa138</ArticleId><ArticleId IdType="pmc">PMC7267830</ArticleId><ArticleId IdType="pubmed">32119072</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.I., Krpina K., Ianevski A., Shtaida N., Jo E., Yang J., Koit S., Tenson T., Hukkanen V., Anthonsen M.W., et al. Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine. Viruses. 2019;11:964. doi: 10.3390/v11100964.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11100964</ArticleId><ArticleId IdType="pmc">PMC6832696</ArticleId><ArticleId IdType="pubmed">31635418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Andersen P.I., Merits A., Bjoras M., Kainov D. Expanding the activity spectrum of antiviral agents. Drug Discov. Today. 2019;24:1224&#x2013;1228. doi: 10.1016/j.drudis.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.04.006</ArticleId><ArticleId IdType="pubmed">30980905</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M.J., Wright R.S., Fairweather D., Senefeld J.W., Bruno K.A., Klassen S.A., Carter R.E., Klompas A.M., Wiggins C.C., Shepherd J.R., et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J. Clin. Investig. 2020;130:4791&#x2013;4797. doi: 10.1172/JCI140200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140200</ArticleId><ArticleId IdType="pmc">PMC7456238</ArticleId><ArticleId IdType="pubmed">32525844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivi G., Teesalu K., Parik J., Kontkar E., Ustav M., Jr., Noodla L., Ustav M., Mannik A. HybriFree: A robust and rapid method for the development of monoclonal antibodies from different host species. BMC Biotechnol. 2016;16:2. doi: 10.1186/s12896-016-0232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12896-016-0232-6</ArticleId><ArticleId IdType="pmc">PMC4706699</ArticleId><ArticleId IdType="pubmed">26747451</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D., Klann K., Koch B., Widera M., Krause D., Ciesek S., Cinatl J., Munch C. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583:469&#x2013;472. doi: 10.1038/s41586-020-2332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2332-7</ArticleId><ArticleId IdType="pubmed">32408336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schafer A., Dinnon K.H., 3rd, Stevens L.J., et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12 doi: 10.1126/scitranslmed.abb5883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId><ArticleId IdType="pmc">PMC7164393</ArticleId><ArticleId IdType="pubmed">32253226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C.H., Wang Y.F., Liu X.J., Lu J.H., Qian C.W., Wan Z.Y., Yan X.G., Zheng H.Y., Zhang M.Y., Xiong S., et al. Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro. Chin. Med. J. (Engl.) 2005;118:493&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">15788131</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bufalo F., Ceglie G., Cacchione A., Alessi I., Colafati G.S., Carai A., Diomedi-Camassei F., De Billy E., Agolini E., Mastronuzzi A., et al. BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas. Front. Oncol. 2018;8:526. doi: 10.3389/fonc.2018.00526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00526</ArticleId><ArticleId IdType="pmc">PMC6246660</ArticleId><ArticleId IdType="pubmed">30488019</ArticleId></ArticleIdList></Reference><Reference><Citation>Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11 doi: 10.1126/scitranslmed.aax5866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId><ArticleId IdType="pmc">PMC6848974</ArticleId><ArticleId IdType="pubmed">31645453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb Y.N. Remdesivir: First Approval. Drugs. 2020 doi: 10.1007/s40265-020-01378-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01378-w</ArticleId><ArticleId IdType="pmc">PMC7459246</ArticleId><ArticleId IdType="pubmed">32870481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>